GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » EBITDA Margin %

ANRO (Alto Neuroscience) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alto Neuroscience's EBITDA for the three months ended in Dec. 2024 was $-14.70 Mil. Alto Neuroscience's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Alto Neuroscience's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


Alto Neuroscience EBITDA Margin % Historical Data

The historical data trend for Alto Neuroscience's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience EBITDA Margin % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
-4,255.71 - - -

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alto Neuroscience's EBITDA Margin %

For the Biotechnology subindustry, Alto Neuroscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's EBITDA Margin % falls into.


;
;

Alto Neuroscience EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alto Neuroscience's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-59.554/0
= %

Alto Neuroscience's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-14.698/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alto Neuroscience  (NYSE:ANRO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Alto Neuroscience EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience Business Description

Traded in Other Exchanges
N/A
Address
369 South San Antonio Road, Los Altos, CA, USA, 94022
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.